Glaxo & Pfizer rejig JV deal with Shionogi

ViiV Healthcare, a joint venture (JV) between drugs giants GlaxoSmithKline and Pfizer, is to acquire the exclusive global rights to the assets of Shionogi-ViiV Healthcare, a JV set up with Shionogi, the Japanese pharmaceuticals firm.

ViiV Healthcare, a joint venture (JV) between drugs giants GlaxoSmithKline and Pfizer, is to acquire the exclusive global rights to the assets of Shionogi-ViiV Healthcare, a JV set up with Shionogi, the Japanese pharmaceuticals firm.

The assets include the investigational medicine dolutegravir and other early stage HIV integrase inhibitor compounds.

As a result of the deal, Shionogi will receive an ongoing royalty and dividend stream, and will also receive a 10% equity in ViiV Healthcare. As a result of this, Glaxo's stake will be diluted to 76.5% and Pfizer's stake will be reduced to 13.5%.

Specifically, Shionogi will receive a royalty on net sales of the integrase inhibitor portfolio averaging in the high teens. For a defined period post-launch, while the franchise gets itself established, the royalty applies to sales above certain minimum thresholds; after that period, the royalty applies to all sales.

Shionogi will be entitled to representation on the ViiV Healthcare board, and will, for a defined period, continue to have ongoing involvement in the formulation of the development and commercialisation plans for the integrase inhibitor portfolio.

The deal kicks in on October 31st, and replaces the existing joint venture agreement between ViiV Healthcare and Shionogi.

With ViiV Healthcare in exclusive control of the development and commercialisation rights to the integrase inhibitor portfolio, the hope is that this will streamline research & development and commercial operations.

"Both ViiV Healthcare and Shionogi believe that now is the right time to simplify and evolve their existing arrangement," said David Redfern, Chairman of the board of Viiv Healthcare. "In doing so, we will deepen the relationship as shareholders and at board level. We will also unlock synergies through simplifying processes and avoiding duplication. We believe this new agreement will create long-term value for ViiV Healthcare and its shareholders," he added.

Glaxo will continue to consolidate 100% of ViiV Healthcare into its consolidated financial statements. The portion of ViiV Healthcare's after-tax profit attributable to the non-controlling interests of Pfizer and Shionogi will be reflected in the Glaxo income statement.

As a result of this transaction a non-cash accounting gain is expected to be recognised in Glaxo's fourth quarter 2012 non-core results.

Future royalty payments to Shionogi will be recorded as a reduction of the royalty obligation on Glaxo's balance sheet.

JH

Recommended

Share tips of the week – 19 August
Share tips

Share tips of the week – 19 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Aug 2022
How to invest in smart factories as the “fourth industrial revolution” arrives
Share tips

How to invest in smart factories as the “fourth industrial revolution” arrives

Exciting new technologies and trends are coming together to change the face of manufacturing. Matthew Partridge looks at the companies that will drive…
18 Aug 2022
How to invest today? Look to the past, not the future
Investment strategy

How to invest today? Look to the past, not the future

The past few years have seen so many changes to our way of life that many people said we had entered a “new normal”. But as it turns out, the new norm…
18 Aug 2022
A new legal headache for Haleon
Stocks and shares

A new legal headache for Haleon

Haleon, GSK’s former consumer-products arm, spun off last month, has made a dismal debut on the stockmarket.
17 Aug 2022

Most Popular

How to protect your wealth as inflation hits new record highs
Investment strategy

How to protect your wealth as inflation hits new record highs

UK inflation has hit a new record high of 10.1%. It's going to hurt, says Dominic Frisby. Here's how you can protect your wealth.
17 Aug 2022
How to cut your energy bill
Personal finance

How to cut your energy bill

The energy-price cap will almost double in the autumn. What does this mean for your money, and how can you alleviate the squeeze? Ruth Jackson-Kirby h…
17 Aug 2022
Are GSK’s legal troubles a threat to the firm’s survival?
Biotech stocks

Are GSK’s legal troubles a threat to the firm’s survival?

Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargr…
16 Aug 2022